The U.S. Food and Drug Administration approved Eiger BioPharmaceuticals’ Zokinvy for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
If you are not happy with the results below please do another search
50 search results for:
The United States recorded the country’s largest weekly rise in Covid-19 deaths since August, increasing 32% from the previous week to average about 1,500 people per day, according to a Reuters analysis of state and county reports.
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
It took Oxford University’s brightest minds decades of work to give them the expertise to develop a Covid-19 vaccine.
Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
The U.S. Food and Drug Administration’s PDUFA dates for the last week of November 2020 include a review of Liquidia Technologies’ NDA for LIQ861 for the treatment of pulmonary arterial hypertension (PAH).
The European Commission wants to make it easier for patients to access cheaper generic medicines, a draft EU document seen by Reuters shows, in a move that could cut the revenues of big pharmaceutical firms.
Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.
The U.S. Transportation Security Administration screened 1.047 million passengers on Nov. 22, the highest number since mid-March 2020.
AstraZeneca said on Monday the company’s Covid-19 vaccine could be as much as 90% effective, giving the world’s fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals.